Premature ventricular contraction prevention
Premature ventricular contraction Microchapters |
Differentiating Premature Ventricular Contraction from other Disorders |
---|
Diagnosis |
Treatment |
Case Studies |
Premature ventricular contraction prevention On the Web |
to Hospitals Treating Premature ventricular contraction prevention |
Risk calculators and risk factors for Premature ventricular contraction prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]
Overview
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include:
- [Strategy 1]
- [Strategy 2]
- [Strategy 3]
Recommendations for Secondary Prevention of SCD in Patients With Ischemic Heart Disease
Class I |
1. In patients with ischemic heart disease, who either survive SCA due to VT/VF or experience hemodynamically unstable VT (Level of Evidence: B-R) or stable sustained VT (Level of Evidence: B-NR) not due to reversible causes, an ICD is recommended if meaningful survival greater than 1 year is expected.
2. A transvenous ICD provides intermediate value in the secondary prevention of SCD particularly when the patient’s risk of death due to a VA is deemed high and the risk of nonarrhythmic death (either cardiac or noncardiac) is deemed low based on the patient’s burden of comorbidities and functional status (Level of Evidence: B-R). 3. In patients with ischemic heart disease and unexplained syncope who have inducible sustained monomorphic VT on electrophysiological study, an ICD is recommended if meaningful survival of greater than 1 year is expected (Level of Evidence: B-NR).
|